Breast Cancer Clinical Trial
PROactive Evaluation of Function to Avoid CardioToxicity
Summary
This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.
Eligibility Criteria
Inclusion Criteria:
Participant in the SURVIVE registry
Signed informed consent form for PROACT
Histological diagnosis of any cancer type (patients with treated and clinically stable brain metastasis are acceptable)
Scheduled to receive anti-cancer therapy (radiation therapy is permitted)
Exclusion Criteria:
Contraindication to magnetic resonance imaging (MRI)
Unable to comply with study investigations (in the judgment of the investigator)
Life expectancy less than 1 year
Note: If a patient develops a temporary contraindication (e.g. temporary tissue expanders in breast cancer patients) after the baseline MRI, follow up MRIs will be discontinued for safety for the duration in which the patient has the contraindication. However, once the patient is no longer contraindicated to receiving MRIs, the study schedule may resume with their next scheduled MRI time point from the date of enrollment. Therefore, some time points may be skipped during the patient's enrollment in the study.
Also, if a patient needs a repeat MRI at any time point for any reason (i.e. panic attack during the MRI causing them to not be able to continue, unreadable images, etc.), we may repeat the MRI as long as the patient is willing.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Saint Louis Missouri, 63110, United States
How clear is this clinincal trial information?